Simplex Trading
TSHA icon

Simplex Trading’s Taysha Gene Therapies TSHA Stock Holding History

Simplex Trading’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116K Buy
26,000
+1,800
+7% +$8.37K ﹤0.01% 4911
2025
Q4 		$133K Buy
24,200
+13,700
+130% +$66.5K ﹤0.01% 4683
2025
Q3 		$34K Sell
10,500
-200
-2% -$566 ﹤0.01% 6856
2025
Q2 		$24K Buy
10,700
+8,100
+312% +$17.6K ﹤0.01% 6624
2025
Q1 		$3K Sell
2,600
-20,200
-89% -$33.8K ﹤0.01% 7893
2024
Q4 		$39K Buy
22,800
+22,300
+4,460% +$46.3K ﹤0.01% 6135
2024
Q3 		$1K Sell
500
-16,700
-97% -$36.6K ﹤0.01% 8291
2024
Q2 		$38K Buy
17,200
+5,900
+52% +$17.2K ﹤0.01% 6349
2024
Q1 		$32K Sell
11,300
-7,900
-41% -$16.5K ﹤0.01% 6710
2023
Q4 		$33K Sell
19,200
-400
-2% -$797 ﹤0.01% 6487
2023
Q3 		$61K Buy
+19,600
New +$36.6K ﹤0.01% 5630
2023
Q1 		– Sell
-27,200
Closed -$61K – 10155
2022
Q4 		$61K Buy
27,200
+25,800
+1,843% +$52.2K ﹤0.01% 5632
2022
Q3 		$2K Buy
1,400
+500
+56% +$1.81K ﹤0.01% 9373
2022
Q2 		$3K Buy
+900
New +$3.57K ﹤0.01% 9213

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Simplex Trading's TSHA Position: Q1 2026 in Review

Simplex Trading sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 19,782 shares — an estimated $92K sold.

Simplex Trading first reported a position in TSHA in Q4 2021 and held it in 10 quarters. The position peaked at $109K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Simplex Trading reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 19,782 Taysha Gene Therapies shares in Q1 2026, an estimated $92K.
  • Simplex Trading first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 10 quarters.
  • Simplex Trading's Taysha Gene Therapies position peaked at $109K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.